Skip to content

Mindfulness-Based Stress Reduction in the Management of Chronic Pain and Its Comorbid Depression

Cynthia Marske, Samantha Shah, Aaron Chavira, Caleb Hedberg, Raelin Fullmer, Christopher James Clark, Olivia Pipitone, Paulina Kaiser

Journal of osteopathic medicine September 1, 2020 DOI: 10.7556/jaoa.2020.096 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pre-post study Peer reviewed
Sample size 28
Population Adults aged 34 to 77 years with chronic pain lasting at least 1 year, recruited from a community-based teaching hospital in Corvallis, Oregon
Intervention Mindfulness-based stress reduction (MBSR)
Duration 8-week course with 2.5-hour weekly sessions; self-practice goal of 30 minutes per day, 6 days per week
Measures Patient Health Questionnaire (PHQ-9), Pain Catastrophizing Scale (PCS), Modified Oswestry Disability Index (MO)
Topics Depression Meditation
Key points In this pre-post study of 28 adults with chronic pain, an 8-week MBSR course was associated with significant improvements: PHQ-9 depression scores decreased by a mean of 3.7 points, Pain Catastrophizing Scale scores by 4.6 points, and Modified Oswestry Disability Index percent scores by 9.4%. The authors conclude that MBSR benefited participants' perceptions of pain, mood, and functional capacity in this semi-rural setting.

Abstract

Abstract: Context: Chronic pain (CP) is a common and serious medical condition, with an estimated 100 million people affected in the United States. In the 1990s, opioids were increasingly prescribed to manage chronic pain, and this practice contributed to the opioid epidemic of the 21st century. To combat this epidemic, multidisciplinary approaches to chronic pain management are being researched and implemented.

Objective: To evaluate the clinical effectiveness of an 8-week mindfulness-based stress reduction (MBSR) course implemented in a semi-rural population with chronic pain.

Methods: Participants were recruited from a community-based teaching hospital in Corvallis, Oregon, for a pre-post study. Participants aged 34 to 77 years who reported having chronic pain lasting for at least 1 year before enrollment were included. Participants took an 8-week group MBSR course in 2.5-hour weekly sessions taught by an experienced MBSR instructor. Techniques were self-practiced between sessions with a goal of 30 minutes per day, 6 days per week. Pre- and postsurvey measurements of pain, depression, and functional capacity were taken via online surveys using the patient health questionnaire (PHQ-9), the Pain Catastrophizing Scale (PCS), and a shortened version of the Modified Oswestry Disability Index (MO). Participants were asked about their satisfaction with the program content, instructor, timing, and location.

Results: Twenty-eight participants were included in the study. Paired t tests found significant improvements in PHQ-9, PCS, and MO percent scores from before to after the course. PHQ-9 scores decreased by a mean of 3.7 points (95% CI, −5.5, −1.8), PCS scores decreased by a mean of 4.6 points (95% CI: −7.2, −2.0), and MO percent score decreased by a mean of 9.4% (95% CI: −14.2%, −4.6%). Results showed an overall downward shift in the distribution of depression, disability, and pain scores after the course.

Conclusions: MBSR classes were found to benefit participants with chronic pain and depression in this setting, fostering significant improvement in participant perceptions of pain, mood, and functional capacity.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 4

Cites 12

and 7 more in the library

Explore topics